Online inquiry

IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5768MR)

This product GTTS-WQ5768MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ5768MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9582MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ5231MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CB 2679d
GTTS-WQ14202MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RG4934
GTTS-WQ4692MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986168
GTTS-WQ14160MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aIL6R88
GTTS-WQ6912MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ15139MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SYNT-001
GTTS-WQ13893MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-2176
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW